Skip to main content

Tim Haines, John Rossi, Ambion


People in the News

Life sciences investment group Abingworth Management, which holds a stake in Alnylam Pharmaceuticals, said this week that it has appointed Tim Haines as a partner.

Haines will be responsible for identifying and creating new businesses, as well as providing support for existing companies within the Abingworth portfolio, the firm said.

Haines is currently CEO of Astex Therapeutics, and will join Abingworth in September. Before Astex, he was CEO of two division of the medical technology firm Datascope. He has a BSc from Exeter University and an MBA from INSEAD.

John Rossi, a researcher at City of Hope's Beckman Research Institute, has joined the scientific advisory board of NanoViricides, the company said last week.

Rossi is currently adjunct professor of the division of biomedical sciences at the University of California, Riverside, and adjunct professor in the department of biochemistry and microbiology at Loma Linda University.

He received his PhD in microbial genetics from the University of Connecticut. He also currently sits on the SAB of Calando Pharmaceuticals, which he co-founded, and Benitec. He also is a board member at CytoGenix.

Products & Services

Ambion recently announced the launch of the Silencer CellReady siRNA libraries, a new line of pre-plated, ready-to-transfect siRNA libraries.

According to the company, pre-defined siRNA set includes three individual siRNAs per target plated in the ideal amount for use in a single RNAi screen in human cells. This initial launch will include libraries targeting human kinases and the "druggable" genome, as well as two libraries targeting commonly studied genes.

Additional details about the libraries can be found at

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.